Non-Small Cell Lung Cancer - Pipeline Review, H1 2018

  • ID: 4586020
  • Drug Pipelines
  • 3034 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • BioCancell Ltd
  • Eudendron Srl
  • Immunocore Ltd
  • Multimmune GmbH
  • Rgenix Inc
  • MORE
Non-Small Cell Lung Cancer - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2018, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

Report Highlights:

This latest pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 1, 49, 238, 205, 16, 175, 30 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 13, 14, 46 and 5 molecules, respectively.

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • BioCancell Ltd
  • Eudendron Srl
  • Immunocore Ltd
  • Multimmune GmbH
  • Rgenix Inc
  • MORE
Introduction

Non-Small Cell Lung Cancer - Overview

Non-Small Cell Lung Cancer - Therapeutics Development

Non-Small Cell Lung Cancer - Therapeutics Assessment

Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development

Non-Small Cell Lung Cancer - Drug Profiles

Non-Small Cell Lung Cancer - Dormant Projects

Non-Small Cell Lung Cancer - Discontinued Products

Non-Small Cell Lung Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Non-Small Cell Lung Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by 4D Pharma PLC, H1 2018

Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H1 2018

Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Abpro, H1 2018

Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Adamed Sp z oo, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Aduro BioTech Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Advantagene Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Advaxis Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Agenus Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by AlfaSigma SpA, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Altimmune Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corp, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Amgen Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by AndroScience Corp, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Apexigen Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Arcus Biosciences Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by ARMO Biosciences Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by ArQule Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Asana BioSciences LLC, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Atreca Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Aurobindo Pharma Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Batu Biologics Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H1 2018

Non-Small Cell Lung Cancer - Pipeline by BeiGene Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by BerGenBio ASA, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Beta Pharma Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Bicycle Therapeutics Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by BioAtla LLC, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Biocad, H1 2018

Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Biocon Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by BioLineRx Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Biothera Pharmaceutical Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corp, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical Inc, H1 2018

Non-Small Cell Lung Cancer - Pipeline by BriaCell Therapeutics Corp, H1 2018

Non-Small Cell Lung Cancer - Pipeline by BrightPath Biotherapeutics Co Ltd, H1 2018

Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018

List of Figures

Number of Products under Development for Non-Small Cell Lung Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3-V Biosciences Inc
  • 3SBio Inc
  • 4D Pharma PLC
  • 4SC AG
  • AbbVie Inc
  • Ability Pharmaceuticals SL
  • Abpro
  • ACEA Biosciences Inc
  • Adamed Sp z oo
  • Adaptimmune Therapeutics Plc
  • Aduro BioTech Inc
  • Advantagene Inc
  • Advaxis Inc
  • Advenchen Laboratories LLC
  • Agenus Inc
  • AlfaSigma SpA
  • Allist Shanghai Pharmaceutical Technology Co Ltd
  • Altimmune Inc
  • Altor BioScience Corp
  • Amgen Inc
  • Andarix Pharmaceuticals Inc
  • AndroScience Corp
  • Apexigen Inc
  • Aptose Biosciences Inc
  • Arcus Biosciences Inc
  • Ariad Pharmaceuticals Inc
  • ARMO Biosciences Inc
  • ArQule Inc
  • Array BioPharma Inc
  • Asana BioSciences LLC
  • Ascentage Pharma Group Corp Ltd
  • Astellas Pharma Inc
  • Asterias Biotherapeutics Inc
  • AstraZeneca Plc
  • Atreca Inc
  • Aurigene Discovery Technologies Ltd
  • Aurobindo Pharma Ltd
  • AVEO Pharmaceuticals Inc
  • Basilea Pharmaceutica Ltd
  • Batu Biologics Inc
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Beijing Hanmi Pharmaceutical Co Ltd
  • BerGenBio ASA
  • Beta Pharma Inc
  • Betta Pharmaceuticals Co Ltd
  • BeyondSpring Pharmaceuticals Inc
  • Bicycle Therapeutics Ltd
  • Bio-Cancer Treatment International Ltd
  • BioAtla LLC
  • Biocad
  • BioCancell Ltd
  • Biocon Ltd
  • Biohaven Pharmaceutical Holding Company Ltd
  • BioLineRx Ltd
  • Biothera Pharmaceutical Inc
  • Blueprint Medicines Corp
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • BriaCell Therapeutics Corp
  • BrightPath Biotherapeutics Co Ltd
  • Bristol-Myers Squibb Co
  • Cadila Healthcare Ltd
  • Calithera Biosciences Inc
  • CanBas Co Ltd
  • Cantargia AB
  • Cantex Pharmaceuticals Inc
  • CASI Pharmaceuticals Inc
  • CBT Pharmaceuticals Inc
  • Celgene Corp
  • Cell Medica Ltd
  • Celldex Therapeutics Inc
  • Cellestia Biotech AG
  • Cellmid Ltd
  • Cellular Biomedicine Group Inc
  • Checkmate Pharmaceuticals Inc
  • Checkpoint Therapeutics Inc
  • Chem-Master International Inc
  • Chipscreen Biosciences Ltd
  • Chugai Pharmaceutical Co Ltd
  • Cielo Therapeutics Inc
  • Cleave Biosciences Inc
  • Clovis Oncology Inc
  • Coherus BioSciences Inc
  • Corcept Therapeutics Inc
  • Cortice Biosciences Inc
  • Corvus Pharmaceuticals Inc
  • Cotinga Pharmaceuticals Inc
  • Cristal Therapeutics BV
  • CSPC Pharmaceutical Group Limited
  • CytomX Therapeutics Inc
  • Cytori Therapeutics Inc
  • DAE HWA Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • DanDrit Biotech A/S
  • Debiopharm International SA
  • DEKK-TEC Inc
  • DelMar Pharmaceuticals Inc
  • Domainex Ltd
  • Double Bond Pharmaceutical International AB
  • Dr. Reddy's Laboratories Ltd
  • Dynavax Technologies Corp
  • eFFECTOR Therapeutics Inc
  • Eisai Co Ltd
  • Eleison Pharmaceuticals LLC
  • Eli Lilly and Co
  • EnGeneIC Ltd
  • EntreChem SL
  • Enzene Biosciences Ltd
  • EpiThany Inc
  • Epizyme Inc
  • Eudendron Srl
  • Evotec AG
  • Exelixis Inc
  • F-star Biotechnology Ltd
  • F. Hoffmann-La Roche Ltd
  • FibroStatin SL
  • Five Prime Therapeutics Inc
  • Formosa Laboratories Inc
  • Fountain Biopharma Inc
  • Fresenius SE & Co KGaA
  • Fujifilm Holdings Corporation
  • G&E Corp
  • G1 Therapeutics Inc
  • Galectin Therapeutics Inc
  • Gene Techno Science Co Ltd
  • Genelux Corp
  • Genentech Inc
  • Genmab A/S
  • Genocea Biosciences Inc
  • Genor BioPharma Co Ltd
  • Genosco Inc
  • Genzyme Corp
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • GlycaNova Norway AS
  • Glycotope GmbH
  • Golden Biotechnology Corp
  • Gradalis Inc
  • Grunenthal GmbH
  • Halozyme Therapeutics Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Heat Biologics Inc
  • Helix BioPharma Corp
  • Hemispherx Biopharma Inc
  • Heptares Therapeutics Ltd
  • HitGen LTD
  • Horizon Pharma Plc
  • Hutchison MediPharma Ltd
  • iCeutica Inc
  • Ideaya Biosciences Inc
  • Idera Pharmaceuticals Inc
  • Ignyta Inc
  • Immatics Biotechnologies GmbH
  • Immune Design Corp
  • Immune Pharmaceuticals Inc
  • Immunicum AB
  • Immunocore Ltd
  • ImmunoGen Inc
  • Immunomedics Inc
  • Immutep Ltd
  • Imugene Ltd
  • Incyte Corp
  • Infinity Pharmaceuticals Inc
  • Inflection Biosciences Ltd
  • Innovent Biologics Inc
  • InteRNA Technologies BV
  • Invectys SA
  • Inventiva
  • IO Biotech ApS
  • Io Therapeutics Inc
  • Iovance Biotherapeutics Inc
  • JHL Biotech Inc
  • Jiangsu Hansoh Pharmaceutical Group Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Jounce Therapeutics Inc
  • Juno Therapeutics Inc
  • Kadmon Corp LLC
  • Karyopharm Therapeutics Inc
  • Kite Pharma Inc
  • Kura Oncology Inc
  • Kyowa Hakko Kirin Co Ltd
  • Laboratoires Pierre Fabre SA
  • LATITUDE Pharmaceuticals Inc
  • Leap Therapeutics Inc
  • Les Laboratoires Servier SAS
  • Lidds AB
  • Lotus Pharmaceutical Co Ltd
  • Loxo Oncology Inc
  • Lupin Ltd
  • Luye Pharma Group Ltd
  • Lycera Corp
  • MabVax Therapeutics Holdings Inc
  • mAbxience SA
  • MacroGenics Inc
  • Madrigal Pharmaceuticals Inc
  • MallInckrodt Plc
  • Mebiopharm Co Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Merrimack Pharmaceuticals Inc
  • Mersana Therapeutics Inc
  • Merus NV
  • Millennium Pharmaceuticals Inc
  • Mirati Therapeutics Inc
  • Mitsubishi Tanabe Pharma Corp
  • Moderna Therapeutics Inc
  • Molecular Partners AG
  • MorphoSys AG
  • Morphotek Inc
  • Multimmune GmbH
  • Mycenax Biotech Inc
  • NanoCarrier Co Ltd
  • NantKwest Inc
  • Natco Pharma Ltd
  • Nektar Therapeutics
  • Neumedicines Inc
  • NewLink Genetics Corp
  • Northern Biologics Inc
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Numab Innovation AG
  • Omnitura Therapeutics Inc
  • Oncobiologics Inc
  • Oncolys BioPharma Inc
  • Oncolytics Biotech Inc
  • OncoResponse Inc
  • Ono Pharmaceutical Co Ltd
  • Onxeo SA
  • Optimum Therapeutics LLC
  • OSE Immunotherapeutics
  • Oxford BioTherapeutics Ltd
  • Paranta Biosciences Ltd
  • Peptomyc SL
  • Pfizer Inc
  • Pharma Mar SA
  • Philogen SpA
  • Phosplatin Therapeutics LLC
  • Pique Therapeutics
  • Plexxikon Inc
  • Polaris Pharmaceuticals Inc
  • Precision Biologics Inc
  • Protheragen Inc
  • Provectus Biopharmaceuticals Inc
  • PsiOxus Therapeutics Ltd
  • Puma Biotechnology Inc
  • Purdue Pharma LP
  • Qilu Pharmaceutical Co Ltd
  • Qu Biologics Inc
  • Qurient Co Ltd
  • Rafael Pharmaceuticals Inc
  • RaQualia Pharma Inc
  • Reata Pharmaceuticals Inc
  • Recombio SL
  • RedHill Biopharma Ltd
  • Regeneron Pharmaceuticals Inc
  • Replimune Ltd
  • Revolution Medicines Inc
  • Rexahn Pharmaceuticals Inc
  • Rgenix Inc
  • Richter Gedeon Nyrt
  • RS Research
  • Sanofi
  • Scancell Holdings Plc
  • SciClone Pharmaceuticals Inc
  • ScinoPharm Taiwan Ltd
  • Seattle Genetics Inc
  • Selvita SA
  • SensoPath Technologies Inc
  • Shanghai Henlius Biotech Co Ltd
  • Shanghai Pharmaceutical Co Ltd
  • Shionogi & Co Ltd
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Sierra Oncology Inc
  • SignPath Pharma Inc
  • Simcere Pharmaceutical Group
  • Sino Biopharmaceutical Ltd
  • Soricimed Biopharma Inc
  • Sotio AS
  • Sphaera Pharma Pte Ltd
  • Spotlight Innovation Inc
  • Starpharma Holdings Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • SuviCa Inc
  • Symic Biomedical Inc
  • Symphogen A/S
  • Synactix Pharmaceuticals Inc
  • Syndax Pharmaceuticals Inc
  • Synermore Biologics Co Ltd
  • SyntheX Inc
  • Systimmune Inc
  • Taiho Pharmaceutical Co Ltd
  • Tasly Pharmaceutical Group Co Ltd
  • TC BioPharm Ltd
  • TCR2 Therapeutics Inc
  • TESARO Inc
  • Teva Pharmaceutical Industries Ltd
  • Theralase Technologies Inc
  • Tiziana Life Sciences Plc
  • Tocagen Inc
  • Tolero Pharmaceuticals Inc
  • TRACON Pharmaceuticals Inc
  • Transgene SA
  • Tyme Technologies Inc
  • UbiVac LLC
  • Ultimovacs AS
  • United BioPharma Inc
  • Vaccibody AS
  • Vaccinex Inc
  • VasGene Therapeutics Inc
  • Vault Pharma Inc
  • Vaxon Biotech
  • Verastem Inc
  • VG Life Sciences Inc
  • Viralytics Ltd
  • XBiotech Inc
  • Xencor Inc
  • XuanZhu Pharma Co Ltd
  • Yangtze River Pharmaceutical Group
  • Yooyoung Pharm Co Ltd
  • Zai Lab Ltd
  • Zhejiang Jianfeng Group Company Ltd
  • Zymeworks Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll